{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T02:43:57Z","timestamp":1649213037434},"reference-count":18,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RRCT"],"published-print":{"date-parts":[[2019,1,30]]},"abstract":"<jats:sec>\n<jats:title>Background: <\/jats:title>\n<jats:p>The use of indwelling Central Venous Access Devices (CVADs) is associated\nwith the development of bloodstream infections. When CVADs are used to administer systemic\nantibiotics, particularly second- or higher-generation cephalosporins, there is a particular risk of developing\nClostridium difficile infection. The overall bloodstream infection rate is estimated to be\naround 1.74 per 1000 Central Venous Catheter (CVC)-days.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p> We hypothesised that daily oral administration of the anion-binding resin colestyramine\n(cholestyramine) would help prevent infections in those receiving intravenous antibiotic treatment via\nCVADs.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p> A small case series is described of adult patients who received regular intravenous antibiotic\ntreatment (ceftriaxone, daptomycin or vancomycin) for up to 40 weeks via indwelling CVADs; this\nrepresented a total of 357 CVC-days. In addition to following well-established strategies to prevent C.\ndifficile infection, during the course of the intravenous antibiotic treatment the patients also received\ndaily oral supplementation with 4 g colestyramine.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>There were no untoward infectious events. In particular, none of the patients developed any\nsymptoms or signs of C. difficile infection, whereas approximately one case of a bloodstream infection\nwould have been expected.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> It is suggested that oral colestyramine supplementation may help prevent such infection\nthrough its ability to bind C. difficile toxin A (TcdA) and C. difficile toxin B (TcdB); these toxins are\nable to gain entry into host cells through receptor-mediated endocytosis, while anti-toxin antibody\nresponses to TcdA and TcdB have been shown to induce protection against C. difficile infection\nsequelae.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574887113666180817125036","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T00:51:56Z","timestamp":1535331116000},"page":"47-49","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevention of Infection in Adults Receiving Intravenous Antibiotic Treatment via Indwelling Central Venous Access Devices"],"prefix":"10.2174","volume":"14","author":[{"given":"Basant K.","family":"Puri","sequence":"first","affiliation":[{"name":"Department of Medicine, Imperial College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Derham","sequence":"additional","affiliation":[{"name":"Breakspear Medical Group, Hemel Hempstead, Hertfordshire, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean A.","family":"Monro","sequence":"additional","affiliation":[{"name":"Breakspear Medical Group, Hemel Hempstead, Hertfordshire, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","author":"Buxton I.L.O.","unstructured":"Buxton ILO.  In:","journal-title":""},{"key":"ref=2","author":"Ho C.","unstructured":"Ho C, Spry C.  In:","journal-title":"Central Venous Access Devices (CVADs) and\nPeripherally Inserted Central Catheters (PICCs) for Adult and Pediatric\nPatients: A Review of Clinical Effectiveness and Safety:"},{"key":"ref=3","first-page":"2","author":"Zhang Z.","year":"2018","unstructured":"Zhang Z, Brusasco C, Anile A.  Clinical practice guidelines for the management of central venous catheter for critically ill patients.","journal-title":"J Emerg Crit Care Med"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2012.01.004","volume":"40","author":"Vardakas K.Z.","year":"2012","unstructured":"Vardakas KZ, Polyzos KA, Patouni K.  Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence.","journal-title":"Int J Antimicrob Agents"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.surg.2017.01.018","volume":"162","author":"Napolitano L.M.","year":"2017","unstructured":"Napolitano LM, Edmiston CE.  Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update.","journal-title":"Surgery"},{"key":"ref=6","first-page":"pp. 341-402","author":"McAdam A.J.","year":"2015","unstructured":"McAdam AJ, Milner DA, Sharpe AH In:.","journal-title":"Robbins and Cotran\nPathologic Basis of Disease Kumar, V, Abbas, AK, Aster, JC,\nEds Elsevier Saunders: Philadelphia, PA,"},{"key":"ref=7","first-page":"pp. 749-819","author":"Turner J.R. In:","year":"2015","unstructured":"Turner JR In:.","journal-title":"Robbins and Cotran Pathologic Basis of Disease\nKumar, V, Abbas, AK, Aster, JC, Eds; Elsevier Saunders: Philadelphia,\nPA,"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1200\/JCO.2013.53.3018","volume":"32","author":"Lipitz-Snyderman A.","year":"2014","unstructured":"Lipitz-Snyderman A, Sepkowitz KA, Elkin EB.  Long-term central venous catheter use and risk of infection in older adults with cancer.","journal-title":"J Clin Oncol"},{"key":"ref=9","first-page":"pii: 0148607116678766","author":"Brandt C.F.","year":"2016","unstructured":"Brandt CF, Tribler S, Hvistendahl M.  Home Parenteral Nutrition in Adult Patients With Chronic Intestinal Failure: Catheter-Related Complications Over 4 Decades at the Main Danish Tertiary Referral Center.","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.clnu.2016.03.009","volume":"35","author":"Santarpia L.","year":"2016","unstructured":"Santarpia L, Buonomo A, Pagano MC.  Central venous catheter related bloodstream infections in adult patients on home parenteral nutrition: Prevalence, predictive factors, therapeutic outcome.","journal-title":"Clin Nutr"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mehy.2014.11.020","volume":"84","author":"Puri B.K.","year":"2015","unstructured":"Puri BK, Hakkarainen-Smith JS, Monro JA.  The potential use of cholestyramine to reduce the risk of developing Clostridium difficile-associated diarrhoea in patients receiving long-term intravenous ceftriaxone.","journal-title":"Med Hypotheses"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2982.2012.01988.x","volume":"24","author":"Psichas A.","year":"2012","unstructured":"Psichas A, Little T, Lal S, McLaughlin J.  Colestyramine slows gastric emptying of liquids and reduces appetite in healthy subjects.","journal-title":"Neurogastroenterol Motil"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3390\/toxins6072162","volume":"6","author":"Olling A.","year":"2014","unstructured":"Olling A, H\u00fcls C, Goy S.  The combined repetitive oligopeptides of clostridium difficile Toxin A counteract premature cleavage of the glucosyl-transferase domain by stabilizing protein conformation.","journal-title":"Toxins"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1128\/IAI.01950-14","volume":"82","author":"Baliban S.M.","year":"2014","unstructured":"Baliban SM, Michael A, Shammassian B.  An optimized, synthetic DNA vaccine encoding the Toxin A and Toxin B receptor binding domains of clostridium difficile induces protective Antibody Responses","journal-title":"Infect Immun"},{"key":"ref=15","author":"Committee J.F.","year":"2018","unstructured":"Committee JF.","journal-title":"British National Formulary"},{"key":"ref=16","author":"Birch T.","year":"2018","unstructured":"Birch T, Golan Y, Rizzardini G.  Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection.","journal-title":"J Antimicrob Chemother"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1017\/S0950268817000644","volume":"145","author":"Crowell K.T.","year":"2017","unstructured":"Crowell KT, Julian KG, Katzman M.  Compliance with Clostridium difficile treatment guidelines: Effect on patient outcomes.","journal-title":"Epidemiol Infect"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/14712598.2015.1045872","volume":"15","author":"Borgia G.","year":"2015","unstructured":"Borgia G, Maraolo AE, Foggia M, Buonomo AR, Gentile I.  Fecal microbiota transplantation for Clostridium difficile infection: Back to the future.","journal-title":"Expert Opin Biol Ther"}],"container-title":["Reviews on Recent Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/164741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T12:07:48Z","timestamp":1563883668000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/164741\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,30]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574887113666180817125036","relation":{},"ISSN":["1574-8871"],"issn-type":[{"value":"1574-8871","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}